Literature DB >> 31019898

Objective Response by mRECIST Is an Independent Prognostic Factor of Overall Survival in Systemic Therapy for Hepatocellular Carcinoma.

Masatoshi Kudo1.   

Abstract

Entities:  

Year:  2019        PMID: 31019898      PMCID: PMC6465712          DOI: 10.1159/000497460

Source DB:  PubMed          Journal:  Liver Cancer        ISSN: 1664-5553            Impact factor:   11.740


× No keyword cloud information.
  10 in total

1.  Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib.

Authors:  Maxime Ronot; Mohamed Bouattour; Johanna Wassermann; Onorina Bruno; Chantal Dreyer; Béatrice Larroque; Laurent Castera; Valérie Vilgrain; Jacques Belghiti; Eric Raymond; Sandrine Faivre
Journal:  Oncologist       Date:  2014-03-20

2.  mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib.

Authors:  Tim Meyer; Daniel H Palmer; Ann-Lii Cheng; Julia Hocke; Arsène-Bienvenu Loembé; Chia-Jui Yen
Journal:  Liver Int       Date:  2017-02-02       Impact factor: 5.828

Review 3.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.

Authors: 
Journal:  J Hepatol       Date:  2018-04-05       Impact factor: 25.083

4.  Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.

Authors:  Masatoshi Kudo; Richard S Finn; Shukui Qin; Kwang-Hyub Han; Kenji Ikeda; Fabio Piscaglia; Ari Baron; Joong-Won Park; Guohong Han; Jacek Jassem; Jean Frederic Blanc; Arndt Vogel; Dmitry Komov; T R Jeffry Evans; Carlos Lopez; Corina Dutcus; Matthew Guo; Kenichi Saito; Silvija Kraljevic; Toshiyuki Tamai; Min Ren; Ann-Lii Cheng
Journal:  Lancet       Date:  2018-03-24       Impact factor: 79.321

5.  Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC.

Authors:  Riccardo Lencioni; Robert Montal; Ferran Torres; Joong-Won Park; Thomas Decaens; Jean-Luc Raoul; Masatoshi Kudo; Charissa Chang; José Ríos; Valerie Boige; Eric Assenat; Yoon-Koo Kang; Ho-Yeong Lim; Ian Walters; Josep M Llovet
Journal:  J Hepatol       Date:  2017-01-26       Impact factor: 25.083

6.  Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.

Authors:  Julien Edeline; Eveline Boucher; Yan Rolland; Elodie Vauléon; Marc Pracht; Christophe Perrin; Catherine Le Roux; Jean-Luc Raoul
Journal:  Cancer       Date:  2011-06-28       Impact factor: 6.860

7.  Duration of stable disease is associated with overall survival in patients with advanced hepatocellular carcinoma treated with sorafenib.

Authors:  Tadaaki Arizumi; Kazuomi Ueshima; Hirokazu Chishina; Masashi Kono; Mashiro Takita; Satoshi Kitai; Tatsuo Inoue; Norihisa Yada; Satoru Hagiwara; Yasunori Minami; Toshiharu Sakurai; Naoshi Nishida; Masatoshi Kudo
Journal:  Dig Dis       Date:  2014-10-29       Impact factor: 2.404

8.  Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial.

Authors:  Masatoshi Kudo; Kazuomi Ueshima; Osamu Yokosuka; Sadahisa Ogasawara; Shuntaro Obi; Namiki Izumi; Hiroshi Aikata; Hiroaki Nagano; Etsuro Hatano; Yutaka Sasaki; Keisuke Hino; Takashi Kumada; Kazuhide Yamamoto; Yasuharu Imai; Shouta Iwadou; Chikara Ogawa; Takuji Okusaka; Fumihiko Kanai; Kohei Akazawa; Ken-Ichi Yoshimura; Philip Johnson; Yasuaki Arai
Journal:  Lancet Gastroenterol Hepatol       Date:  2018-04-07

9.  Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis.

Authors:  Bruno Vincenzi; Massimo Di Maio; Marianna Silletta; Loretta D'Onofrio; Chiara Spoto; Maria Carmela Piccirillo; Gennaro Daniele; Francesca Comito; Eliana Maci; Giuseppe Bronte; Antonio Russo; Daniele Santini; Francesco Perrone; Giuseppe Tonini
Journal:  PLoS One       Date:  2015-07-31       Impact factor: 3.240

10.  Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma.

Authors:  Juichi Takada; Hisashi Hidaka; Takahide Nakazawa; Masaaki Kondo; Kazushi Numata; Katsuaki Tanaka; Kotaro Matsunaga; Chiaki Okuse; Satoshi Kobayashi; Manabu Morimoto; Shinichi Ohkawa; Wasaburo Koizumi
Journal:  BMC Res Notes       Date:  2015-10-26
  10 in total
  8 in total

Review 1.  Recent Advances in Systemic Therapy for Hepatocellular Carcinoma in an Aging Society: 2020 Update.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2020-11-17       Impact factor: 11.740

2.  Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma.

Authors:  Angel Alsina; Masatoshi Kudo; Arndt Vogel; Ann-Lii Cheng; Won Young Tak; Baek-Yeol Ryoo; Thomas R Jeffry Evans; Carlos López López; Bruno Daniele; Soamnauth Misir; Min Ren; Namiki Izumi; Shukui Qin; Richard S Finn
Journal:  Liver Cancer       Date:  2019-12-16       Impact factor: 11.740

3.  Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma.

Authors:  Keisuke Koroki; Naoya Kanogawa; Susumu Maruta; Sadahisa Ogasawara; Yotaro Iino; Masamichi Obu; Tomomi Okubo; Norio Itokawa; Takahiro Maeda; Masanori Inoue; Yuki Haga; Atsuyoshi Seki; Shinichiro Okabe; Yoshihiro Koma; Ryosaku Azemoto; Masanori Atsukawa; Ei Itobayashi; Kenji Ito; Nobuyuki Sugiura; Hideaki Mizumoto; Hidemi Unozawa; Terunao Iwanaga; Takafumi Sakuma; Naoto Fujita; Hiroaki Kanzaki; Kazufumi Kobayashi; Soichiro Kiyono; Masato Nakamura; Tomoko Saito; Takayuki Kondo; Eiichiro Suzuki; Yoshihiko Ooka; Shingo Nakamoto; Akinobu Tawada; Tetsuhiro Chiba; Makoto Arai; Tatsuo Kanda; Hitoshi Maruyama; Jun Kato; Naoya Kato
Journal:  Liver Cancer       Date:  2021-04-20       Impact factor: 11.740

4.  Baseline angiopoietin-2 and FGF19 levels predict treatment response in patients receiving multikinase inhibitors for hepatocellular carcinoma.

Authors:  Taku Shigesawa; Goki Suda; Megumi Kimura; Tomoe Shimazaki; Osamu Maehara; Ren Yamada; Takashi Kitagataya; Kazuharu Suzuki; Akihisa Nakamura; Masatsugu Ohara; Machiko Umemura; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Naoya Sakamoto
Journal:  JGH Open       Date:  2020-04-11

5.  Changes in Serum Growth Factors during Lenvatinib Predict the Post Progressive Survival in Patients with Unresectable Hepatocellular Carcinoma.

Authors:  Zijian Yang; Goki Suda; Osamu Maehara; Masatsugu Ohara; Sonoe Yoshida; Shunichi Hosoda; Megumi Kimura; Akinori Kubo; Yoshimasa Tokuchi; Qingjie Fu; Ren Yamada; Takashi Kitagataya; Kazuharu Suzuki; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Shunsuke Ohnishi; Naoya Sakamoto
Journal:  Cancers (Basel)       Date:  2022-01-04       Impact factor: 6.639

6.  Early Predictors of Objective Response in Patients with Hepatocellular Carcinoma Undergoing Lenvatinib Treatment.

Authors:  Issei Saeki; Takahiro Yamasaki; Satoyoshi Yamashita; Tadasuke Hanazono; Yohei Urata; Takakazu Furutani; Yuichiro Yokoyama; Toshiyuki Oishi; Masaki Maeda; Teruaki Kimura; Yurika Kotoh; Ryo Sasaki; Takashi Miyaji; Takashi Oono; Yuki Aibe; Takuro Hisanaga; Takuya Iwamoto; Toshihiko Matsumoto; Isao Hidaka; Tsuyoshi Ishikawa; Taro Takami; Isao Sakaida
Journal:  Cancers (Basel)       Date:  2020-03-25       Impact factor: 6.639

Review 7.  Evaluation of liver tumour response by imaging.

Authors:  Jules Gregory; Marco Dioguardi Burgio; Giuseppe Corrias; Valérie Vilgrain; Maxime Ronot
Journal:  JHEP Rep       Date:  2020-04-28

8.  Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma.

Authors:  Kei Amioka; Tomokazu Kawaoka; Masanari Kosaka; Yusuke Johira; Yuki Shirane; Ryoichi Miura; Serami Murakami; Shigeki Yano; Kensuke Naruto; Yuwa Ando; Yumi Kosaka; Yasutoshi Fujii; Kenichiro Kodama; Shinsuke Uchikawa; Hatsue Fujino; Atsushi Ono; Takashi Nakahara; Eisuke Murakami; Wataru Okamoto; Masami Yamauchi; Michio Imamura; Nami Mori; Shintaro Takaki; Keiji Tsuji; Keiichi Masaki; Yoji Honda; Hirotaka Kouno; Hiroshi Kohno; Takashi Moriya; Noriaki Naeshiro; Michihiro Nonaka; Hideyuki Hyogo; Yasuyuki Aisaka; Takahiro Azakami; Akira Hiramatsu; Hiroshi Aikata
Journal:  Cancers (Basel)       Date:  2022-01-10       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.